A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
Thématique(s) / pathologie(s)
- Maladie de Parkinson
Objectifs
Plus d'informations disponibles sur : https://clinicaltrials.gov/ct2/show/NCT03100149?term=pasadena&cond=Parkinson&rank=1
Promoteur
Hoffmann-La Roche
Publication(s) scientifique(s)
-
Jankovic J et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214.
Statut
Résultats publiés